In view of the advancement in the understanding about the most diverse types of cancer and
consequently a relentless search for a cure and increased survival rates of cancer patients …

Simple Summary Within this review article the authors provide an unbiased review of the
oncolytic virus, reovirus, clinically formulated as pelareorep. In particular, the authors …

Oncogenic Ras mutants, frequently detected in human cancers, are high-priority anticancer
drug targets. However, direct inhibition of oncogenic Ras mutants with small molecules has …

Reovirus is an oncolytic virus with activity in in vivo models of malignant gliomas (MGs). The
primary aims were to determine the dose‐limiting toxicity (DLT) and maximum tolerated …

Reovirus is a double-stranded RNA virus with demonstrated oncolysis or preferential
replication in cancer cells. The oncolytic properties of reovirus appear to be dependent, in …

Purpose: Early clinical trials are under way exploring the direct oncolytic potential of
reovirus. This study addresses whether tumor infection by reovirus is also able to generate …

The use of replicating viruses for cancer therapy (virotherapy) holds much promise. We
reported previously that the live attenuated Edmonston B vaccine strain of measles virus …

Reovirus is a benign human virus that was recently found to have oncolytic properties and is
currently in clinical trials as a potential cancer therapy. We have previously demonstrated …

Oncolytic viruses can exert their antitumor activity via direct oncolysis or activation of
antitumor immunity. Although reovirus is currently under clinical investigation for the …

In the search for novel strategies, oncolytic virotherapy has recently emerged as a viable
approach to specifically kill tumor cells. Unlike conventional gene therapy, it uses replication …